Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

BOSTON and TORONTO, Feb 11 (Bernama) -- Helus PharmaTM (“Helus”) (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.

Mr. Cola’s appointment comes at a pivotal moment as Helus advances its pipeline of next-generation mental health therapies toward key clinical and corporate value-inflection milestones, including the expected release of Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 2026. In parallel, Helus continues to build a broad and defensible intellectual property estate spanning its multi-asset pipeline, with more than 350 patent applications filed globally and over 100 patents granted. The Company is advancing differentiated programs designed to address serious mental health disorders. With the transition from early clinical development to later-stage execution underway, the Company is increasingly focused on global regulatory engagement and long-term commercial planning. This evolution underscores the importance of experienced leadership across drug development, capital formation, and global scale-up.